10x Genomics, Inc.
TXG
$27.94
-$1.01-3.49%
| Weiss Ratings | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.72 | |||
| Price History | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.00% | |||
| 30-Day Total Return | -12.25% | |||
| 60-Day Total Return | -14.18% | |||
| 90-Day Total Return | -23.80% | |||
| Year to Date Total Return | -33.24% | |||
| 1-Year Total Return | -33.46% | |||
| 2-Year Total Return | -41.71% | |||
| 3-Year Total Return | -80.61% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -54.13% | |||
| 52-Week Low % Change | 0.14% | |||
| Price | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $63.57 | |||
| 52-Week Low Price | $29.12 | |||
| 52-Week Low Price (Date) | Apr 17, 2024 | |||
| 52-Week High Price (Date) | Jul 31, 2023 | |||
| Valuation | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.47B | |||
| Enterprise Value | 3.18B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.18 | |||
| Earnings Per Share Growth | 49.05% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 5.59 | |||
| Price/Book (Q) | 4.69 | |||
| Enterprise Value/Revenue (TTM) | 5.14 | |||
| Price | $36.25 | |||
| Enterprise Value/EBITDA (TTM) | -19.61 | |||
| Enterprise Value/EBIT | -16.09 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 118.57M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 925 401 7300 | |||
| Address | 6230 Stoneridge Mall Road Pleasanton, CA 94588-3260 | |||
| Website | www.10xgenomics.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -31.95% | |||
| Profit Margin | -41.22% | |||
| Management Effectiveness | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.39% | |||
| Return on Equity | -- | |||
| Income Statement | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 618.73M | |||
| Total Revenue (TTM) | 618.73M | |||
| Revenue Per Share | $5.22 | |||
| Gross Profit (TTM) | 409.31M | |||
| EBITDA (TTM) | -162.22M | |||
| EBIT (TTM) | -197.73M | |||
| Net Income (TTM) | -255.10M | |||
| Net Income Avl. to Common (TTM) | -255.10M | |||
| Total Revenue Growth (Q YOY) | 17.76% | |||
| Earnings Growth (Q YOY) | -184.36% | |||
| EPS Diluted (TTM) | -2.18 | |||
| EPS Diluted Growth (Q YOY) | -175.27% | |||
| Balance Sheet | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 388.70M | |||
| Cash Per Share (Q) | $3.28 | |||
| Total Current Assets (Q) | 596.02M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 741.04M | |||
| Current Ratio (Q) | 4.687 | |||
| Book Value Per Share (Q) | $6.22 | |||
| Total Assets (Q) | 965.14M | |||
| Total Current Liabilities (Q) | 127.16M | |||
| Total Debt (Q) | 95.37M | |||
| Total Liabilities (Q) | 224.10M | |||
| Total Common Equity (Q) | 741.04M | |||
| Cash Flow | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 133.49M | |||
| Cash from Financing (TTM) | 13.67M | |||
| Net Change in Cash (TTM) | 131.93M | |||
| Levered Free Cash Flow (TTM) | 28.89M | |||
| Cash from Operations (TTM) | -15.20M | |||
